Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Capital lowered shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Trading Down 3.4 %

CYCC stock opened at $0.66 on Wednesday. Cyclacel Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $10.12. The business’s 50-day moving average is $1.02 and its 200 day moving average is $1.53. The stock has a market cap of $1.41 million, a price-to-earnings ratio of -0.04 and a beta of 0.51.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative net margin of 21,963.75% and a negative return on equity of 1,901.11%. During the same period in the previous year, the business earned ($6.60) earnings per share. As a group, equities analysts forecast that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.